Absstract of: EP3309550A1

The present invention provides a method for the detection of Apolipoprotein E isotype 4 (ApoE4) or fragments thereof in a blood sample of a subject, whereby said method comprises the steps of contacting said sample with a solid phase, contacting said sample with at least one binder binding specifically to ApoE4 or a fragment thereof, thereby forming an ApoE4binder-complex, and detecting the ApoE4-binder-complex.

Absstract of: WO2021219917A1

The present invention relates to a method for preparing a plasma sample comprising amyloid beta peptides for analysis by mass spectrometry, comprising the steps of: a) placing said plasma sample in contact with a denaturing agent, b) performing a first solid phase extraction step on the solution obtained in step a) to recover a first eluate, c) performing a second solid phase extraction step on said first eluate obtained in step b) to recover a second eluate, and d) drying said second eluate obtained in step c) and processing it for analysis by mass spectrometry, wherein the solution obtained in step d) comprises intact amyloid beta peptides Aß40 and Aß42.

Absstract of: US2023003721A1

Described herein is a multiplexed and high content screening assay using primary neurons for identifying small molecule modulators of neuronal mitochondrial mitostasis (MnMs). Also described is a high throughput screening assay using primary neurons for identifying small molecules that increase mitochondrial function, identified by measuring the electrochemical potential across the inner mitochondrial membrane and ATP generation. Most MnMs that increased mitochondrial content, length and/or health also increased mitochondrial function without altering neurite outgrowth. Some MnMs protect mitochondria in primary neurons from Aβ(1-42) toxicity, glutamate toxicity, increased oxidative stress and the toxic cellular environment associated with Alzheimer's disease. Some MnMs target mitochondria directly. An MnM also increases the synaptic activity of hippocampal neurons and is potent in vivo, increasing the respiration rate of brain mitochondria after administering the compound to mice. The MnMs were demonstrated to protect the mitochondrial population in neurons in an in vivo model of Alzheimer's Disease. Also described is a method for treating a patient suffering from a disorder characterized by dysfunction of neuronal mitostasis, comprising administering to the patient a therapeutically effective amount of a compound (MnM), or a pharmaceutically acceptable salt thereof.

Absstract of: WO2023272576A1

Provided in the present application is a marker of Alzheimer's disease, which marker comprises monocyte chemoattractant protein-1 (MCP 1). Further provided in the present application are a method for detecting the marker of Alzheimer's disease, a kit for detecting Alzheimer's disease, and the use of the marker, the detection method and the kit in the screening of a drug for treating Alzheimer's disease.

Absstract of: WO2023277459A1

The present invention relates to a screening method of a therapeutic agent for brain diseases. Specifically, the screening method according to the present invention can be useful for screening a therapeutic agent for brain diseases. The screening method is based on the fact that Rg3, which is known to have a therapeutic effect for Alzheimer's disease, promotes NF-κB signaling mechanisms while promoting M2 polarization and suppressing M1 polarization, suppresses Aβ accumulation by increasing SRA protein expression, and suppresses water-soluble APPα processing in neural cells through water-soluble APPα generation and the suppression of Aβ42 generation by increasing ADAM10 protein expression in microglia or neuroblastoma.

Absstract of: US2023003744A1

Embodiments of the disclosure are directed to biomarkers, or a panel of biomarkers, that determine progression of Alzheimer's disease, and methods of use thereof.

Absstract of: US2022411489A1

Provided herein are modified immunoglobulins comprising an amyloid reactive peptide joined to an antibody, as well as humanized antibodies that bind to human amyloid fibrils and antibody-peptide fusion proteins. Also provided herein are methods of treating amyloid-based diseases by administering a modified immunoglobulin, humanized antibody, or antibody-peptide fusion protein.

Absstract of: US2022412949A1

A composition having one or more nanoneedles is provided, where each nanoneedle has a silver tip and one or more of the silver tips comprise an AgCl layer. In one approach, one or more of the silver tips further include a layer of thiol-polyethylene glycol. A method of resistive pulse detection involving a protein pore is also provided. The method involves reconstituting one or more protein pores in a lipid membrane formed on the tip of a nanoneedle, then applying a potential across the membrane and detecting resistive pulses.

Absstract of: WO2022270112A1

[Abstract] Corosolic acid improves insulin resistance and recovers an insulin function that is deteriorated with age. As a result, the insulin sensitivity in an aged person is improved and the metabolism in all cells gets active. [Problem] The problem to be solved by the present invention is to alleviate and ameliorate an adult disease, a lifestyle-related disease, dementia and the like associated with insulin resistance and achieve a long healthy life-span by corosolic acid and an analogue thereof. There is a finding about a composition which recovers a function inherent to insulin again against the slowing down of an insulin reaction or insulin resistance that is believed as a main cause of an adult disease, a lifestyle-related disease, dementia or the like and is consequently useful for the delay of progression or prevention of an adult disease, a lifestyle-related disease, dementia/Alzheimer's disease or the like, and an idea about a specific method is proposed.

Absstract of: WO2021165465A1

The present invention relates to a method for assessing atrial fibrillation in a subject, said method comprising the steps of determining the amount of BMP10 in a sample from the subject, and comparing the amount of BMP10 to a reference amount, whereby atrial fibrillation is to be assessed. Moreover, the present invention relates to a method for diagnosing heart failure based on the determination of BMP10 in a sample from a subject. Further, the present invention relates to a method for predicting the risk of a subject of hospitalization due to heart failure based on the determination of a BMP10-type peptide in a sample from a subject. The present invention further pertains to antibodies which bind to one or more BMP10-type peptides such as NT-proBMP10.

Absstract of: US2018265575A1

Monoclonal anti-PHF-tau antibodies and antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, methods of producing the antibodies and using the antibodies for treating or preventing conditions such as tauopathies.

Absstract of: NZ748983A

The present invention relates to a class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PHF) tau (pS396) with improved affinity, as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer s disease and other tauopathies.

Absstract of: US2022402979A1

The disclosure provides immunogenic peptides, compositions, means, and methods for treating Alzheimer's disease or mild cognitive impairment. The disclosure further provides means and methods for diagnosing patients, selecting patients for treatment, and/or evaluating the efficacy of treatment for Alzheimer's disease or mild cognitive impairment.

Absstract of: WO2022265723A1

The disclosure provides compounds, salts and methods of use thereof for the prevention, treatment, delay of onset and management of Alzheimer's disease.

Absstract of: US2022403011A1

Provided are novel specific binding molecules, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize neoepitopes of disease-associated proteins which derive from native endogenous proteins but are prevalent in the body of a patient in a variant form and/or out of their normal physiological context. In addition, pharmaceutical compositions comprising such binding molecules, antibodies and mimics thereof and methods of screening for novel binding molecules, which may or may not be antibodies as well as targets in the treatment of neurological disorders such as Alzheimer's disease are described.

Absstract of: US2022406435A1

Methods are provided for the prognosis, diagnosis and treatment of various pathological states, including cancer, chemotherapy resistance and dementia associated with Alzheimer's disease. The methods provided herein are based on the discovery that various proteins with a high level of sialylation are shown herein to be associated with disease states, such as, cancer, chemotherapy resistance and dementia associated with Alzheimer's disease. Such methods provide a lysosomal exocytosis activity profile comprising one or more values representing lysosomal exocytosis activity. Also provided herein, is the discovery that low lysosomal sialidase activity is associated with various pathological states. Thus, the methods also provide a lysosomal sialidase activity profile, comprising one or more values representing lysosomal sialidase activity. A lysosomal sialidase activity profile is one example of a lysosomal exocytosis activity profile.

Absstract of: US2022404376A1

The present invention concerns a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound selected in the group comprising (i) a polypeptide comprising an amino acid sequence selected in the group comprising the amino acid sequence of the long isoform in Homo sapiens of the RdCVF2 gene (SEQ ID NO: 10), orthologs, derivatives and fragments thereof, (ii) a polynucleotide coding for said polypeptide, (iii) a vector comprising said polynucleotide, and (iv) a host cell genetically engineered expressing said polypeptide; the use of such a composition for the manufacture of a medicament for treating and/or preventing a neurodegenerative disorder in a subject; and a method of testing a subject thought to have or be predisposed to having a neurodegenerative disorder.

Absstract of: US2022397566A1

Current application relates to the field of neurodegenerative diseases. More specifically, the present invention relates to screening methods to identify compounds that can reduce the production of amyloidogenic Amyloid beta fragments. Said compounds can be used in treatments of for example Alzheimer's disease.

Absstract of: WO2022261413A1

Described herein are cell-based high-throughput screening (HTS) assays for the identification of activators of γ-secretase.

Absstract of: US2022397580A1

The present disclosure relates generally to the field of neurology. In particular, the disclosure relates to a method of detecting a neurodegenerative disease in a subject and methods of treatment thereof. The methods include detecting the level of an exosome-bound aggregated biomarker in a sample obtained from the subject, wherein an increased level of the exosome-bound aggregated biomarker as compared to a reference indicates that the subject is suffering from a neurodegenerative disease. Also described are methods for detecting a subject at risk of developing amyloidosis or a neurodegenerative disease, methods for detecting and treating amyloidosis or a neurodegenerative disease in a subject, and methods of determining the aggregation state of a biomarker in a sample.

Absstract of: EP4101465A1

The present invention provides a kit for use in determining tauopathy or a dementia-related disease (excluding Alzheimer's disease), containing an antibody that recognizes a polypeptide consisting of (1) the amino acid sequence shown in SEQ ID NO: 1, or (2) an amino acid sequence resulting from substitution, deletion, addition or insertion of one to several amino acids in the amino acid sequence shown in SEQ ID NO: 1, and the like.

Absstract of: WO2018062859A1

The present invention relates to a method for detecting small RNAs or proteins associated with the small RNAs. More specifically, the present invention relates to a method for detecting small RNAs or proteins associated with the small RNAs using a single nucleic acid which has a structure of X-Y-Z and consists of base sequences capable of complementary binding with all or a part of the base sequence of small RNAs to be detected. Since the present invention can quickly and accurately detect small RNAs or proteins associated with the small RNAs, the present invention can be usefully used for diagnosis of various diseases and diagnosis of prognosis.

Absstract of: EP3124034A1

An anti-aging agent derived from a natural product is provided. The agent uses at least one selected from the group consisting of an imidazole dipeptide and a metabolite thereof as an active ingredient. The present invention also provides an agent for improving a neuropsychologic function, which contains at least one selected from the group consisting of an imidazole dipeptide and a metabolite thereof as an active ingredient. The present invention also provides an agent for changing expression of a transporter such as SLC23A2, which contains at least one selected from the group consisting of an imidazole dipeptide and a metabolite thereof, and an agent for controlling blood concentration of a cytokine such as IP-10, which contains at least one selected from the group consisting of an imidazole dipeptide and a metabolite thereof, as well as an expression analysis method for detecting improvement or degradation of a neuropsychologic function, and a kit for detecting improvement or degradation of a neuropsychologic function.

Absstract of: WO2021228125A1

The present invention provides protein markers present in a person's blood sample (such as a plasma, serum, or whole blood sample) that are associated with the Alzheimer's Disease (AD), diagnostic and treatment methods for AD, and kits for diagnosing AD.

Absstract of: AU2021273299A1

The present invention provides protein markers present in a person's blood sample (such as a plasma, serum, or whole blood sample) that are associated with the Alzheimer's Disease (AD), diagnostic and treatment methods for AD, and kits for diagnosing AD.